Miriam Cruz joined Turning Point Therapeutics in June 2018 as vice president of clinical operations. She is responsible for all strategic and tactical elements of clinical operations, including the phase 2 registrational study for lead asset repotrectinib. Her experience includes nearly 20 years in positions of increasing responsibility within the pharmaceutical and biotech industry. She previously led the Phase 1b/2 EBV+ lymphoma trial and clinical operations function at Viracta Therapeutics, where she served as vice president of clinical operations. She also led the pivotal global Phase 3 PDA trial for Halozyme Therapeutics and has experience with trial management, from study initiation through study completion/primary data analysis and in multiple phases of clinical development. Ms. Cruz also held senior positions at Eisai, Merck and Schering Plough. She earned a Bachelor of Science in biology from the City College of New York (CUNY). Ms. Cruz, a member of the American Society of Clinical Oncology and the European Society of Medical Oncology, believes in the importance of working directly with physicians and patients to address unmet needs in healthcare and cancer treatment.